| Objective: To investigate the effect of trimetazidine on quality of life(Qo L) and exercise tolerance in patients with coronary heart disease(CHD) combined atrial fibrillation(AF).Methods: The information of 62 patients with coronary heart disease(CHD) combined atrial fibrillation(AF) from october 2014 to october 2015 in the cardiology department of our hospital were prospectively analyzed. All patients were divided into the trimetazidine group(n=29) and the standard group(n=33) according to the different treatment methods. The patients of the two groups were both given the conventional drugs treatment, such as beta-blockers, aspirin, clopidogrel, calcium channel blockers, statins, while the patients of the trimetazidine group were added with trimetazidine treatment(20mg/d,three times a day) for 6 months,the 6-minute walk testand Qo Lof patients were measured. The 6-minute walk testand Qo L(SF36)of patients in the two groups were evaluated after the treatment.Results:A total 62 patients were received,The conventional group(n=33) including 42%(14/33) males,58%(19/33) females,mean age 72.55±7.25 years,mean BMI 23.23±2.18,mean LVEF 60.64±11.80,mean Borg 1.02±0.71.The trimetazidine group(n=29) including 45%(13/29) males,55%(16/29) females,mean age 74.14±8.35 years,mean BMI 23.83±2.47,mean LVEF 60.34±10.21,mean Borg 0.81±0.44.Follow-up 6 months,there were no statistical significance between the two groups in Age, gender, past medical history, BMI, medication compliance, whether PCI surgery,Borg grade,etc(P>0.05).6-minute walk test is carried out after the patient is treated for six months. Then, the experiment compares the members of patients within the group. The follow-up distance(351.79±83.21) of the normal treatment group after receiving 6-month treatment is noticeably longer than before(302.72±71.26), which is of statistical significance(P=0.00<0.05). The walking distance(377.38±60.36) of the trimetazidinegroup after receiving 6-month treatment is noticeably longer than before(310.66±42.89). And it is of statistical significance(P=0.00<0.05). After comparing the difference of the two groups, it is found that the trimetazidine group(92.48±61.30) has a better performance than the normal treatment group(49.07±90.19). The comparative result is of statistical significance(P=0.03<0.05).After studying follow-up results of in-group comparisons before and after 6-month treatment according to the SF 36 scale, the normal treatment group’s physical components(PCS)(P=0.40) and mental components(MCS)(P=0.83) are both of non-statistical significance(P>0.05); the trimetazidine group’s physical components(PCS)(P=0.00) and mental components(MCS)(P=0.00) are both of statistical significance(P<0.05). When studying follow-up results of between-group comparison before 6-month treatment, PCS(P=0.39) and MCS(P=0.88) are both of non-statistical significance(P>0.05); The between-group comparison after 6-month treatment shows that PCS(P=0.39) and MCS(P=0.88) are both of non-statistical significance(P>0.05). The SF 36 scale is divided into 8 dimensions, the in-group comparison carried for the control group after receiving 6-month treatment, PF and RE are of statistical significance after treatment and the remaining 6 items are of non-statistical significance(P>0.05). After comparing the test group before and after 6-month treatment, PF, RP, BP, GH, VT, SF and RE are of statistical significance(P<0.05). Only MH is of non-statistical significance(P<0.05). The between-group comparison shows that the 8 dimensions are of non-statistical significance before 6-month treatment. And after 6-month treatment, the life quality of PF, RP, BP, GH, VT, SF and RE are all of-statistical significance both before and after treatment, with only MH of non-statistical significance.Conclusion:Trimetazidine can improve exercise tolerance(6-minute walk test) and the quality of life in patients with coronary heart disease combined atrial fibrillation. |
PDF Full Text Request